NexgenRx Gestione

Gestione criteri di controllo 2/4

NexgenRx Il CEO è Ron Loucks, nominato in Mar2003, e ha un mandato di 21.67 anni. la retribuzione annua totale è CA$ 313.34K, composta da 75% di stipendio e 25% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 10.48% delle azioni della società, per un valore di CA$ 2.20M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.5 anni e 12.5 anni.

Informazioni chiave

Ron Loucks

Amministratore delegato

CA$313.3k

Compenso totale

Percentuale dello stipendio del CEO	75.0%
Mandato del CEO	21.7yrs
Proprietà del CEO	10.5%
Durata media del management	5.5yrs
Durata media del Consiglio di amministrazione	12.5yrs

Aggiornamenti recenti sulla gestione

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 10

Recent updates

Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 45% But Growth Is Lacking

May 21

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 10

NexgenRx Inc.'s (CVE:NXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 19

How Much Is NexgenRx's (CVE:NXG) CEO Getting Paid?

Dec 28

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Ron Loucks rispetto agli utili di NexgenRx?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-CA$25k
Mar 31 2024	n/a	n/a	-CA$66k
Dec 31 2023	CA$313k	CA$235k	-CA$332k
Sep 30 2023	n/a	n/a	-CA$310k
Jun 30 2023	n/a	n/a	-CA$244k
Mar 31 2023	n/a	n/a	-CA$172k
Dec 31 2022	CA$287k	CA$235k	-CA$22k
Sep 30 2022	n/a	n/a	CA$3m
Jun 30 2022	n/a	n/a	CA$4m
Mar 31 2022	n/a	n/a	CA$4m
Dec 31 2021	CA$230k	CA$215k	CA$4m
Sep 30 2021	n/a	n/a	CA$2m
Jun 30 2021	n/a	n/a	CA$2m
Mar 31 2021	n/a	n/a	CA$2m
Dec 31 2020	CA$153k	CA$140k	CA$2m
Sep 30 2020	n/a	n/a	CA$1m
Jun 30 2020	n/a	n/a	CA$483k
Mar 31 2020	n/a	n/a	-CA$31k
Dec 31 2019	CA$181k	CA$165k	-CA$208k
Sep 30 2019	n/a	n/a	CA$38k
Jun 30 2019	n/a	n/a	-CA$147k
Mar 31 2019	n/a	n/a	-CA$438k
Dec 31 2018	CA$181k	CA$165k	-CA$697k
Sep 30 2018	n/a	n/a	-CA$1m
Jun 30 2018	n/a	n/a	-CA$1m
Mar 31 2018	n/a	n/a	-CA$793k
Dec 31 2017	CA$181k	CA$165k	-CA$626k

Compensazione vs Mercato: La retribuzione totale di Ron ($USD 222.40K ) è superiore alla media delle aziende di dimensioni simili nel mercato Canadian ($USD 170.34K ).

Compensazione vs guadagni: La retribuzione di Ron è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Ron Loucks (74 yo)

21.7yrs

Mandato

CA$313,342

Compensazione

Mr. Ronald C. Loucks, also known as Ron, B.B.A. Founded NexgenRx, Inc. in March 2003 and has been its Chief Executive Officer and President since March 2003. Mr. Loucks has over 25 years of experience in t...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Ronald Loucks	Founder	21.7yrs	CA$313.34k	10.48% CA$ 2.2m
Kelly Elher	Chief Financial Officer	7.5yrs	CA$60.00k	0.63% CA$ 132.5k
Andrew Munroe	Vice President of Operations	less than a year	CA$169.40k	Nessun dato
Jason Robinson	Vice President of Administration	no data	Nessun dato	Nessun dato
Doreen Harvey	Lead Human Resources	no data	Nessun dato	Nessun dato
Paul Bolger	Company Secretary	3.4yrs	Nessun dato	Nessun dato
Avik Debroy	Financial Controller	no data	Nessun dato	Nessun dato

5.5yrs

Durata media

Gestione esperta: Il team dirigenziale di NXG è esperto e expertise (durata media dell'incarico 5.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Ronald Loucks	Founder	21.7yrs	CA$313.34k	10.48% CA$ 2.2m
Thomas Corcoran	Independent Chairman	18.7yrs	CA$30.00k	0.88% CA$ 184.5k
Linda Brennan	Director	less than a year	Nessun dato	Nessun dato
Randolf McGlynn	Independent Director	6.3yrs	CA$20.00k	0.14% CA$ 29.5k

12.5yrs

Durata media

74yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di NXG è composto da personale esperto e esperto (durata media dell'incarico 12.5 anni).

NexgenRx Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

NexgenRx Inc. Announces Appointment of Linda Brennan to Its Board of Directors

Charles Burns Tenders Resignation as Director of NexgenRx Inc

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

NexgenRx Inc., Annual General Meeting, May 16, 2024

Insufficient new directors

NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of Directors

Recent updates

NexgenRx Inc. Announces Appointment of Linda Brennan to Its Board of Directors

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: EPS: CA$0 (vs CA$0 in 2Q 2023)

Dividend of CA$0.005 announced

NexgenRx Inc. Declares Dividend in Respect of All of Its Outstanding Common Shares, Payable on or Before June 30, 2024

Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 45% But Growth Is Lacking

First quarter 2024 earnings released: EPS: CA$0.006 (vs CA$0.003 in 1Q 2023)

Charles Burns Tenders Resignation as Director of NexgenRx Inc

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Full year 2023 earnings released: CA$0.005 loss per share (vs CA$0 in FY 2022)

NexgenRx Inc., Annual General Meeting, May 16, 2024

NexgenRx Inc.'s (CVE:NXG) Price Is Out Of Tune With Revenues

Insufficient new directors

NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of Directors

NEXGENRX Inc Announces Declaration of Dividend, Payable on or Before January 4, 2024

Third quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.001 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: CA$0 (vs CA$0 in 2Q 2022)

NexgenRx Inc. Announces Declaration of Dividend in Respect of All of Its Outstanding Common Shares , Payable on or Before June 30, 2023

High number of new directors

First quarter 2023 earnings released: EPS: CA$0.003 (vs CA$0.005 in 1Q 2022)

NexgenRx Inc. Appoints Dave Bennett as New Director

Insufficient new directors

Full year 2022 earnings released

Here's Why We Think NexgenRx (CVE:NXG) Might Deserve Your Attention Today

Insufficient new directors

Now 23% undervalued

Third quarter 2022 earnings released

Insufficient new directors

Is Now The Time To Put NexgenRx (CVE:NXG) On Your Watchlist?

NexgenRx Inc. Announces Dividend on its outstanding common shares, payable on or Before October 10, 2022

NexgenRx Inc. Announces Dividend on its outstanding common shares, Payable on Payable on or Before October 10, 2022

Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.005 profit in 2Q 2021)

First quarter 2022 earnings released: EPS: CA$0.005 (vs CA$0.005 in 1Q 2021)

Insufficient new directors

NexgenRx Inc., Annual General Meeting, May 19, 2022

Full year 2021 earnings released: EPS: CA$0.055 (vs CA$0.029 in FY 2020)

Does NexgenRx (CVE:NXG) Deserve A Spot On Your Watchlist?

Third quarter 2021 earnings released: EPS CA$0.006 (vs CA$0.007 in 3Q 2020)

Insufficient new directors

What NexgenRx Inc.'s (CVE:NXG) 32% Share Price Gain Is Not Telling You

Second quarter 2021 earnings released: EPS CA$0.005 (vs CA$0.007 in 2Q 2020)

Here's Why NexgenRx Inc.'s (CVE:NXG) CEO May Have Their Pay Bumped Up

First quarter 2021 earnings released: EPS CA$0.005 (vs CA$0.004 in 1Q 2020)

Full year 2020 earnings released: EPS CA$0.03 (vs CA$0.003 loss in FY 2019)

New 90-day high: CA$0.34

NexgenRx Inc.'s (CVE:NXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

New 90-day high: CA$0.30

How Much Is NexgenRx's (CVE:NXG) CEO Getting Paid?

New 90-day high: CA$0.23

Third quarter 2020 earnings released: EPS CA$0.007

NexgenRx Inc.(TSXV:NXG) dropped from S&P/TSX Venture Composite Index

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media